AMGN · Amgen Inc
$376.03
+4.53 (+1.22%)
At close · Jul 24
Market Cap
$202.95B
Shares
539.71M
Amgen Inc Earnings Call Transcripts
Every quarterly earnings call for Amgen Inc (AMGN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲1%
$6.59B
$1.32B
'22 Q2
22-08-04
▼0.8%
$6.65B
$2.14B
'22 Q3
22-11-03
▼0.1%
$6.84B
$1.62B
'22 Q4
23-01-31
▼2.1%
$6.11B
$2.84B
'23 Q1
23-04-27
▲5.9%
$6.99B
$1.38B
'23 Q2
23-08-03
▲3.8%
$6.90B
$1.73B
'23 Q3
23-10-31
▲19.8%
$8.20B
$767.00M
'23 Q4
24-02-06
▲22%
$7.45B
−$113.00M
'24 Q1
24-05-02
▲20.1%
$8.39B
$746.00M
'24 Q2
24-08-06
▲23.2%
$8.50B
$2.83B
'24 Q3
24-10-30
▲10.9%
$9.09B
$627.00M
'24 Q4
25-02-04
▲9.4%
$8.15B
$1.73B
'25 Q1
25-05-01
▲9.4%
$9.18B
$1.43B
'25 Q2
25-08-05
▲12.4%
$9.56B
$3.22B
'25 Q3
25-11-04
▲8.6%
$9.87B
$1.33B
'25 Q4
26-02-03
LATEST
▲5.8%
$8.62B
$1.82B
'26 Q1
26-04-30
Earnings call
FY26 · Q1
2026-04-30
Amgen Inc Q1 FY2026 Earnings Call
Confident tone
Meritide (MariTide) obesity pipeline
Repatha cardiovascular franchise
Key growth drivers portfolio
Revenue
$8.62B
▲ 5.8% YoY Diluted EPS
$3.34
▲ 4.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-03
Amgen Inc Q4 FY2025 Earnings Call
Positive tone
Meritide obesity pipeline
Growth drivers (Repatha, Evenity, TestSpire)
Tavneos / ChemoCentryx FDA request for withdrawal
Revenue
$9.87B*
▲ 8.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Amgen Inc Q3 FY2025 Earnings Call
Confident tone
Cardiovascular franchise (Repatha, Olpasiran)
Rare diseases and UPLIZNA expansion
Volume growth and broad portfolio momentum
Revenue
$9.56B
▲ 12.4% YoY Diluted EPS
$5.93
▲ 13.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Amgen Inc Q2 FY2025 Earnings Call
Confident tone
MariTide obesity program
Oncology and BiTE platform
General medicine portfolio (Repatha, EVENITY, Prolia)
Revenue
$9.18B
▲ 9.4% YoY Diluted EPS
$2.65
▲ 92% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Amgen Inc Q1 FY2025 Earnings Call
Confident tone
Obesity / MariTide
Rare disease (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS)
Cardiovascular / Repatha
Revenue
$8.15B
▲ 9.4% YoY Diluted EPS
$3.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-04
Amgen Inc Q4 FY2024 Earnings Call
Confident tone
Pipeline catalysts (MariTide, rocatinlimab, oncology)
Repatha expansion
Rare disease portfolio / TEPEZZA international
Revenue
$9.09B*
▲ 10.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Amgen Inc Q3 FY2024 Earnings Call
Confident tone
Rare disease franchise (Horizon)
MariTide (obesity/obesity-related pipeline)
General medicine growth (Repatha, EVENITY, Prolia)
Revenue
$8.50B
▲ 23.2% YoY Diluted EPS
$5.22
▲ 62.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Amgen Inc Q2 FY2024 Earnings Call
Confident tone
MariTide / obesity pipeline
Oncology launches and label expansions
Pipeline breadth and 2024 milestones
Revenue
$8.39B
▲ 20.1% YoY Diluted EPS
$1.38
▼ 46.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Amgen Inc Q1 FY2024 Earnings Call
Confident tone
TEPEZZA safety/monitoring and subcutaneous development
MariTide (obesity/obesity-related conditions/diabetes)
Rare disease / Horizon integration
Revenue
$7.45B
▲ 22% YoY Diluted EPS
$-0.21
▼ 104% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-06
Amgen Inc Q4 FY2023 Earnings Call
Positive tone
Horizon Acquisition / Rare Disease Pillar
MariTide / Obesity Pipeline
Volume Growth & Geographic Expansion
Revenue
$8.20B*
▲ 19.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Amgen Inc Q3 FY2023 Earnings Call
Revenue
$6.90B
▲ 3.8% YoY Diluted EPS
$3.22
▼ 19.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Amgen Inc Q2 FY2023 Earnings Call
Revenue
$6.99B
▲ 5.9% YoY Diluted EPS
$2.57
▲ 4.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Amgen Inc Q1 FY2023 Earnings Call
Revenue
$6.11B
▼ 2.1% YoY Diluted EPS
$5.28
▲ 97% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-31
Amgen Inc Q4 FY2022 Earnings Call
Revenue
$6.84B*
▼ 0.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Amgen Inc Q3 FY2022 Earnings Call
Revenue
$6.65B
▼ 0.8% YoY Diluted EPS
$3.98
▲ 20.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Amgen Inc Q2 FY2022 Earnings Call
Revenue
$6.59B
▲ 1% YoY Diluted EPS
$2.45
▲ 202.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Amgen Inc Q1 FY2022 Earnings Call
Revenue
$6.24B
▲ 5.7% YoY Diluted EPS
$2.68
▼ 5.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-07
Amgen Inc Q4 FY2021 Earnings Call
Revenue
$6.85B*
▲ 3.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Amgen Inc Q3 FY2021 Earnings Call
Revenue
$6.71B
▲ 4.4% YoY Diluted EPS
$3.31
▼ 3.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Amgen Inc Q2 FY2021 Earnings Call
Revenue
$6.53B
▲ 5.2% YoY Diluted EPS
$0.81
▼ 73.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-27
Amgen Inc Q1 FY2021 Earnings Call
Revenue
$5.90B
▼ 4.2% YoY Diluted EPS
$2.83
▼ 7.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-02
Amgen Inc Q4 FY2020 Earnings Call
Revenue
$6.63B*
▲ 7.1% YoY Diluted EPS
$2.76
▼ 3.2% YoY Gross margin
71.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-28
Amgen Inc Q3 FY2020 Earnings Call
Revenue
$6.42B
▲ 12% YoY Diluted EPS
$3.43
▲ 4.9% YoY Gross margin
70.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-28
Amgen Inc Q2 FY2020 Earnings Call
Revenue
$6.21B
▲ 5.7% YoY Diluted EPS
$3.05
▼ 14.6% YoY Gross margin
71.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Amgen Inc Q1 FY2020 Earnings Call
Revenue
$6.16B
▲ 10.9% YoY Diluted EPS
$3.07
▼ 3.5% YoY Gross margin
71.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–25 of 25 earnings calls
Key facts
CIK
318154
CUSIP
031162100
13F (30d)
1085 filings
1064 filers
Visit website
Investor relations